Niagen Bioscience (NAGE) Non-Current Debt (2016)
Niagen Bioscience (NAGE) reported Non-Current Debt of $3.3 million for Q1 2016.
Niagen Bioscience (NAGE) Non-Current Debt (2016) Analysis & Trends
Niagen Bioscience (NAGE) has 1 years of Non-Current Debt data on file, last reported at $3.3 million in Q1 2016.
- Non-Current Debt for Q1 2016 came in at $3.3 million, changed N/A year-over-year; the trailing twelve-month figure through Jan 2016 was $3.3 million (changed N/A YoY), and the FY2016 annual result was $3.3 million, changed N/A from the prior year.
- Non-Current Debt held at $3.3 million in Q1 2016 per NAGE's latest filing.
- Over five years, Non-Current Debt peaked at $3.3 million in Q1 2016 and troughed at $3.3 million in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Niagen Bioscience | 269.32 Mn | 202.77 Mn | 19.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 2, 2016 | 3.35 Mn |
| Jan 2, 2016 | 3.35 Mn |